A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes was launched in The presentation will be webcast live at the aforementioned time, and archived for viewing 90 days thereafter, via the Company's website at www.viacyte.com , under the News and Events Section. About ViaCyte ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.
http://ift.tt/14SDNuu
http://ift.tt/14SDNuu
No comments:
Post a Comment